<https://doi.org/10.1038/s41467-019-10456-x>

OPEN

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

Jennifer L. Caswell-Jin ¹, Katherine McNamara ^{1,2,3}, Johannes G. Reiter ⁴, Ruping Sun ^{1,2,3}, Zheng Hu^{1,2,3}, Zhicheng Ma^{1,2,3}, Jie Ding^{1,2,3}, Carlos J. Suarez⁵, Susanne Tilk⁶, Akshara Raghavendra⁷, Victoria Forte^{8,9}, Suet-Feung Chin ¹⁰, Helen Bardwell¹⁰, Elena Provenzano¹¹, Carlos Caldas ¹⁰, Julie Lang ^{9,12}, Robert West⁵, Debu Tripathy ⁷, Michael F. Press^{9,13} & Christina Curtis ^{1,2,3}

Correction to: *Nature Communications* <https://doi.org/10.1038/s41467-019-08593-4>, published online 08 February 2019.

The original version of this Article omitted from the Author Contributions statement that ‘R.S. and J.G.R. contributed equally to this work.’ This has been corrected in both the PDF and HTML versions of the Article.

Published online: 30 May 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

¹Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford 94305 California, United States. ²Department of Genetics, Stanford University School of Medicine, Stanford 94305 CA, USA. ³Stanford Cancer Institute, Stanford University School of Medicine, Stanford 94305 CA, USA. ⁴Canary Center for Cancer Early Detection, Department of Radiology, Stanford University School of Medicine, Palo Alto 94305 CA, USA. ⁵Department of Pathology, Stanford University School of Medicine, Stanford 94305 CA, USA. ⁶Department of Biology, Stanford University, Stanford 94305 CA, USA. ⁷Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030 TX, USA. ⁸Maimonides Medical Center, Brooklyn 11219 NY, USA. ⁹Norris Comprehensive Cancer Center, Los Angeles 90033 CA, USA. ¹⁰Cancer Research UK Cambridge Institute, Department of Oncology, University of Cambridge, Cambridge CB2 0RE, UK. ¹¹Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK. ¹²Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles 90033 CA, USA. ¹³Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles 90033 CA, USA. These authors contributed equally: Jennifer L. Caswell-Jin, Katherine McNamara, Johannes G. Reiter, Ruping Sun. Correspondence and requests for materials should be addressed to C.C. (email: ncurtis@stanford.edu)